Could a common blood thinner replace warfarin for LVAD patients?
NCT ID NCT07471139
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two blood thinners—apixaban (Eliquis) and warfarin (Coumadin)—in 460 people with advanced heart failure who have a HeartMate 3 heart pump. The goal is to see which drug better prevents strokes, pump clots, and serious bleeding. Participants must have had their pump for at least 3 months and be currently on warfarin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apixaban (Eliquis) compared to warfarin (Coumadin)
- What this could lead to
- If successful, this could offer a simpler, more effective blood thinner for LVAD patients, reducing strokes and bleeding complications.
- What could go wrong
- This is a phase 3 trial, but it has not yet started recruiting. Apixaban may not prove superior or could have unexpected side effects in this specific device population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal zaps could reboot breathing after brain injury
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Can brain scans reveal hidden language struggles after stroke?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?